Clinical Trial Update: A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370) [Phase 1]

View source ↗

Summary

Phase 1 study of pegylated interferon alfa-2b (MK-4031) as adjuvant treatment in Japanese patients with malignant melanoma was terminated; results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Pegylated interferon alfa-2b (MK-4031) (pegylated interferon alfa-2b)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Malignant Melanoma | Phase 1 | Status: TERMINATED | Results posted: 2015-02-11